Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC
June 22, 2022
Pasithea Therapeutics Corp. acquired all outstanding equity interests in Alpha-5 Integrin, LLC, a preclinical biotechnology company developing a monoclonal antibody targeting α5 integrin for ALS and other neuroinflammatory disorders. The transaction was valued at $3.75 million and was paid primarily in Pasithea common stock (3,260,870 shares) plus warrants; an entity controlled by Paul B. Manning was Alpha-5's majority owner prior to the deal.
- Buyers
- Pasithea Therapeutics Corp.
- Targets
- Alpha-5 Integrin, LLC
- Sellers
- An entity controlled by Paul B. Manning
- Industry
- Biotechnology
- Location
- United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Pasithea Therapeutics Acquires AlloMek Therapeutics
October 11, 2022
Biotechnology
Pasithea Therapeutics Corp. (Nasdaq: KTTA) acquired AlloMek Therapeutics, LLC, obtaining the preclinical MEK 1/2 inhibitor CIP-137401 to expand its CNS-focused drug-development pipeline. The deal closed on October 11, 2022 and included $1.05 million in upfront cash, issuance of restricted stock and warrants, plus potential clinical/regulatory milestones and royalties.
-
AbbVie Acquires Aliada Therapeutics for $1.4 Billion
December 11, 2024
Biotechnology
AbbVie has completed the $1.4 billion acquisition of Aliada Therapeutics, a RA Capital- and JJDC-backed biotech developing ALIA-1758, an anti‑pyroglutamate amyloid beta antibody that uses a blood‑brain‑barrier crossing technology for Alzheimer's disease. The deal brings Aliada's CNS drug‑delivery platform and lead Phase 1 asset into AbbVie's neuroscience pipeline and represents an exit for RA Capital's Raven incubator and other early investors.
-
Vertex Pharmaceuticals Acquires Alpine Immune Sciences
April 10, 2024
Biotechnology
Vertex Pharmaceuticals will acquire Alpine Immune Sciences for $65 per share (approximately $4.9 billion) in cash. The acquisition adds Alpine’s lead candidate povetacicept (ALPN‑303) and protein-engineering/immunotherapy capabilities to Vertex’s pipeline and is expected to close in Q2 2024, subject to customary conditions.
-
Sorrento Therapeutics Acquires ACEA Therapeutics
June 1, 2021
Biotechnology
Sorrento Therapeutics completed the acquisition of ACEA Therapeutics, making ACEA a wholly owned subsidiary and issuing Sorrento common stock plus contingent milestone and royalty payments. The deal adds multiple clinical- and preclinical-stage new chemical entities (including abivertinib) to Sorrento's oncology and immunotherapy pipeline and expands its development and manufacturing footprint in China and North America.
-
Arcline Investment Management Acquires Polypeptide Therapeutic Solutions (PTS)
April 27, 2021
Biotechnology
Arcline Investment Management, a growth-oriented private equity firm, has acquired Polypeptide Therapeutic Solutions, S.L. (PTS) from Columbus Venture Partners. PTS is a Valencia-based GMP CDMO specializing in polyamino-acid (PAA) nanoparticle encapsulation and related drug-delivery services; Arcline plans to scale GMP production and expand the company's technology portfolio to support mRNA, gene/cell therapies, biologics and vaccines.
-
Innoviva Acquires Entasis Therapeutics
May 23, 2022
Biotechnology
Innoviva, Inc. agreed to acquire all outstanding shares of Entasis Therapeutics it did not already own for $2.20 per share in cash, valuing Entasis' equity at approximately $113 million on a fully diluted basis. The transaction makes Entasis a wholly owned subsidiary of Innoviva and advances Innoviva's strategy to expand into differentiated late-stage biopharmaceutical assets, including Entasis' lead antibacterial candidate SUL-DUR.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.